Zhitong Finance App News, Jianyou Co., Ltd. (603707.SH) issued an announcement. The company's subsidiary Jianjin Pharmaceutical Co., Ltd. recently received an ANDA approval notice for elibulin mesylate injection (1mg/2mL) issued by the US Food and Drug Administration (“US FDA”). This drug is suitable for patients with metastatic breast cancer who have previously received at least two chemotherapy regimens, and patients with unresectable or metastatic liposarcoma who have previously received treatment regimens containing anthracyclines. The newly approved products further enrich the company's international product pipeline and strengthen the company's international market layout.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.